Two Sigma Advisers’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $228K | Sell |
17,100
-102,400
| -86% | -$1.37M | ﹤0.01% | 2070 |
|
|
2025
Q1 | $1.22M | Buy |
119,500
+98,800
| +477% | +$1.01M | ﹤0.01% | 1382 |
|
|
2024
Q4 | $328K | Buy |
20,700
+13,800
| +200% | +$218K | ﹤0.01% | 1946 |
|
|
2024
Q3 | $401K | Sell |
6,900
-10,900
| -61% | -$633K | ﹤0.01% | 1796 |
|
|
2024
Q2 | $813K | Buy |
17,800
+3,500
| +24% | +$160K | ﹤0.01% | 1658 |
|
|
2024
Q1 | $947K | Buy |
+14,300
| New | +$947K | ﹤0.01% | 1611 |
|
|
2021
Q4 | – | Sell |
-18,800
| Closed | -$744K | – | 2722 |
|
|
2021
Q3 | $744K | Buy |
18,800
+11,300
| +151% | +$447K | ﹤0.01% | 1751 |
|
|
2021
Q2 | $319K | Buy |
7,500
+3,000
| +67% | +$128K | ﹤0.01% | 2116 |
|
|
2021
Q1 | $277K | Buy |
+4,500
| New | +$277K | ﹤0.01% | 2250 |
|